Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs

被引：0
|
作者：
Ye, J. [1 ]
Liu, J. [1 ]
Yang, Y. [1 ]
Lv, W. [1 ]
Xu, W. [2 ]
Xia, P. [1 ]
Wang, L. [1 ]
Zhu, L. [1 ]
Hu, J. [1 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Sanmen Peoples Hosp, Taizhou, Peoples R China
[3] Key Lab Clin Evaluat Technol Med Device Zhejiang, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Anlotinib; NSCLC; EGFR-TKIs;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.04
引用
收藏
页码：S554 / S554
页数：1
相关论文
共 50 条
  • [1] The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
    Xu, T.
    Shen, H.
    Lu, B.
    Wei, C.
    Wang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S476 - S477
  • [2] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [3] Efficacy of 3rd Generation EGFR-TKIs After Failing First or Second Generation EGFR-TKIs in EGFR Mutation-Positive NSCLC (ROOT-EGFR)
    Jung, H. A.
    Hong, S.
    Park, J.
    Park, M. R.
    Sun, J.
    Lee, S.
    Ahn, J. S.
    Ahn, M.
    Park, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S853 - S853
  • [4] EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
    Jiang, Tao
    Chu, Qian
    Wang, Huijuan
    Zhou, Fei
    Gao, Guanghui
    Chen, Xiaoxia
    Li, Xuefei
    Zhao, Chao
    Xu, Qinghua
    Li, Wei
    Wu, Fengying
    Xiong, Anwen
    Zhao, Jing
    Xu, Yaping
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    Hirsch, Fred R.
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2605 - 2612
  • [5] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2024, 24 (01)
  • [6] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
    Jiang, T.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Evolving therapeutic landscape of EGFR-TKIs in NSCLC
    Feng, Chenfeina
    Li, Rendong
    Li, Xiaolei
    Xu, Xinping
    MCB Molecular and Cellular Biomechanics, 2024, 21
  • [8] Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Zheng, Aimin
    Huang, Guanghui
    Li, Wenhong
    Wang, Jiao
    Han, Xiaoying
    Meng, Min
    Ni, Yang
    ONCOTARGET, 2017, 8 (34) : 56714 - 56725
  • [9] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
    Jiang, Tao
    Zhang, Yongchang
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Yang, Nong
    Zhou, Caicun
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108
  • [10] Continued EGFR-TKIs treatment promotes the survival of elderly patients with acquired resistance to EGFR-TKIs therapy
    Wang, P.
    Zhang, D.
    Li, X. -M.
    Guo, X. -G.
    Sun, B. -J.
    Fang, X. -Q.
    Qu, G. -P.
    An, L.
    Liu, C. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (11) : 2450 - 2459
12345